Agentis Longevity, a provider of precision-based longevity healthcare, announced it has acquired BioDesign, a Florida-based longevity and wellness healthcare company, to expand its clinical footprint and deepen its personalized longevity and performance medicine offerings.
The company said the transaction adds BioDesign locations in Tampa, Orlando, Lake Mary, and Melbourne, Florida, and is expected to broaden Agentis Longevity’s diagnostic capabilities, clinical programs, and preventative and performance services. Agentis described BioDesign as known for a science-backed, data-driven approach to long-term health optimization.
Following the acquisition, Agentis said it will deliver greater personalization across program areas, including metabolic health, hormone optimization, cardiovascular health, performance recovery, cellular regeneration, and healthspan extension. BioDesign Co-Founder Jeremy Avner is expected to take on a strategic clinical leadership role focused on diagnostic strategy, therapeutic programming, and innovation.
Agentis said the integration will expand offerings across advanced diagnostic testing and biomarker analysis; personalized longevity health programs; hormone, metabolic, and cardiovascular optimization; recovery and performance therapies; remote monitoring and continuous biomarker tracking; and concierge and mobile services nationwide. The company positioned the deal as part of its effort to build a comprehensive longevity platform serving athletes, executives, entertainers, and others focused on improving performance and long-term health.
KEY QUOTES
“BioDesign’s commitment to personalized, data-driven care aligns perfectly with our mission to drive the standard as the most trusted, transformative provider of longevity care. This acquisition strengthens our ability to deliver the science-backed, highly individualized programs our clients expect. Together, we’re building the most comprehensive longevity platform in the country.”
Jimmy St. Louis, Chief Executive Officer, Agentis Longevity
“At BioDesign, our focus has always been to help men understand their bodies at a deeper level and create longevity-focused programs rooted in precision data. Partnering with Agentis Longevity gives us the opportunity to bring that mission to a broader audience. With Agentis’ national reach and commitment to performance-based medicine, we can elevate the standard of personalized care and help more people optimize their healthspan today and for decades to come.”
Jeremy Avner, Co-Founder, BioDesign Men’s Clinic
“From a clinical standpoint, this acquisition allows us to better align the interests and needs of consumers with high-quality, safe, and innovative healthcare. By integrating our advanced diagnostics and therapeutic model into the Agentis ecosystem, we can deliver even more precise, medically rigorous care that supports long-term performance, prevention, and healthspan extension.”
Jimmy Barker, Co-Founder, BioDesign
“This partnership represents a powerful opportunity to scale the BioDesign model while preserving our commitment to science-backed, individualized care. Our shared vision with Agentis Longevity is centered on the belief that people deserve access to high-quality, safe, and innovative healthcare that aligns with their goals not a one-size-fits-all system. Together, we will continue elevating the standard for longevity and performance medicine nationwide.”
Ian Costello, Co-Founder, BioDesign
